Matching-Adjusted Indirect Comparison of Risankizumab Versus Deucravacitinib in Patients with Moderate-to-Severe Plaque Psoriasis

被引：0
|
作者：
April W. Armstrong [1 ]
Ahmed M. Soliman [2 ]
Paolo Gisondi [3 ]
Siran Fang [2 ]
Manish Patel [2 ]
Bruce Strober [4 ]
机构：
[1] University of Southern California,Department of Dermatology, Keck School of Medicine
[2] AbbVie Inc.,Department of Medicine, Section of Dermatology and Venereology
[3] University of Verona,Department of Dermatology
[4] Yale University,undefined
[5] Central Connecticut Dermatology,undefined
来源：
Dermatology and Therapy | 2024年 / 14卷 / 11期
关键词：
Deucravacitinib; Matching-adjusted indirect comparison; Plaque psoriasis; Risankizumab;
D O I：
10.1007/s13555-024-01293-y
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3071 / 3081
页数：10
相关论文
共 50 条
  • [21] FEASIBILITY OF MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF OMALIZUMAB (OMA) VS. MEPOLIZUMAB (MEPO) IN MODERATE-TO-SEVERE ASTHMA
    Ayyagari, R.
    Alvares, L.
    Mu, F.
    Hacking, V
    Martinez, R.
    Signorovitch, J. E.
    VALUE IN HEALTH, 2016, 19 (07) : A549 - A549
  • [22] MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY OF TRALOKINUMAB AND DUPILUMAB IN THE TREATMENT OF MODERATE-TO-SEVERE ATOPIC DERMATITIS BEYOND WEEK 16
    Torres, Tiago
    Sohrt Petersen, Anne
    Mariela Rosso, Aldana
    Moreira Taveira, Christian
    Manuel Carrascosa, Jose
    ACTA DERMATO-VENEREOLOGICA, 2023, 103 : 48 - 48
  • [23] Correction: Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis
    Tiago Torres
    Anne Sohrt Petersen
    Ulla Ivens
    Albert Bosch Vilaro
    John Stinson
    José Manuel Carrascosa
    Dermatology and Therapy, 2025, 15 (2) : 473 - 475
  • [24] Cost per responder for risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis in Italy
    Gisondi, Paolo
    Loconsole, Francesco
    Raimondo, Paola
    Ravasio, Roberto
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2021, 8 : 120 - 130
  • [25] Efficacy of switching to risankizumab compared with continued adalimumab treatment in patients with moderate-to-severe plaque psoriasis
    Ryan, C.
    Crowley, J.
    Valdecantos, W.
    Wu, T.
    Reich, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 20 - 21
  • [26] Efficacy of risankizumab in moderate-to-severe plaque psoriasis by baseline characteristics and prior therapies
    Strober, B.
    Valdecantos, W.
    Zhan, T.
    Lambert, J.
    Menter, A.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 42 - 43
  • [27] Risankizumab: A Review in Moderate to Severe Plaque Psoriasis
    Hannah A. Blair
    Drugs, 2020, 80 : 1235 - 1245
  • [28] Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis
    Li, Wendy
    Ghamrawi, Rima
    Haidari, Wasim
    Feldman, Steven R.
    ANNALS OF PHARMACOTHERAPY, 2020, 54 (04) : 380 - 387
  • [29] Efficacy of switching to risankizumab compared with continued adalimumab treatment in patients with moderate-to-severe plaque psoriasis
    Ryan, Caitriona
    Crowley, Jeffrey
    Valdecantos, Wendell
    Wu, Tianshuang
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB55 - AB55
  • [30] Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis
    Rand, Kim
    Ramos-Goni, Juan Manuel
    Akmaz, Bulent
    Sole-Feu, Laia
    Armario-Hita, Jose-Carlos
    DERMATOLOGY AND THERAPY, 2024, 14 (01) : 169 - 182
12345